Edouard Samarut1, Alexandre Lugat2,3, Aymeric Amelot4,5, Emeric Scharbarg2, Samy Hadjadj2, Claire Primot6, Delphine Loussouarn7, François Thillays8, Kevin Buffenoir1, Bertrand Cariou2, Delphine Drui9, Vincent Roualdes10. 1. Neurotraumatology, Neurosurgery Department, Hotel-Dieu, CHU Nantes, Nantes, France. 2. L'institut du thorax, Endocrinology, Diabetology and Nutrition Department, CHU Nantes, Nantes, France. 3. Inserm UMR 1232, CRCINA, Université d'Angers, Université de Nantes, Nantes, France. 4. Neurosurgery Department, Bretonneau Hospital, CHRU Tours, Tours, France. 5. Inserm UMR 1253, Université de Tours, Tours, France. 6. Inserm UMR 1413, CIC, Endocrinology, Diabetology and Nutrition, CHU Nantes, Nantes, France. 7. Pathology Department, Hotel-Dieu, CHU Nantes, Nantes, France. 8. Radiotherapy Department, Institut de Cancérologie de l'Ouest (ICO), Saint-Herblain, France. 9. L'institut du thorax, Endocrinology, Diabetology and Nutrition Department, CHU Nantes, Nantes, France. delphine.drui@chu-nantes.fr. 10. Neurotraumatology, Neurosurgery Department, Hotel-Dieu, CHU Nantes, Nantes, France. vincent.roualdes@chu-nantes.fr.
Abstract
PURPOSE: Meningiomas are the most common intracranial tumors, accounting for 20-30% of central nervous system tumors. Recently, the European Medicines Agency issued an alert on cyproterone acetate (CPA) based on the results of a study that found an increased risk of meningioma 7 to 20 times higher when a patient is on CPA. The primary objective of this study was to determine the prevalence of CPA exposure in patients who had one or more intracranial meningiomas treated surgically or with radiation therapy. The secondary objectives were to establish a description of the patients who had intracranial meningioma in Nantes and to establish whether there was a difference in the intrinsic and tumoral characteristics of patients exposed to CPA compared with patients who had no hormonal exposure and patients who had been exposed to other hormones. METHODS: Monocentric, retrospective study including all patients treated by surgery or radiotherapy for intracranial meningioma from 2014 to 2017 excluding those with a history of exposure to ionizing radiation or neurofibromatosis type 2. RESULTS: 388 patients were included, 277 were treated by surgery and 111 by radiotherapy. 3.9% of the patients had a history or current use of CPA, 16.2% were taking other hormonal treatment. Compared with the group without hormonal exposure, the CPA-exposed group had significantly an earlier onset of meningiomas at 48.9 vs. 61.9 years (p = 0.0005) and had more multiple meningiomas, 26.7% vs. 6.1% (p = 0.0115). CONCLUSIONS: In our study, patients with a history or current use of CPA had significantly more meningiomas and were significantly younger at the onset.
PURPOSE:Meningiomas are the most common intracranial tumors, accounting for 20-30% of central nervous system tumors. Recently, the European Medicines Agency issued an alert on cyproterone acetate (CPA) based on the results of a study that found an increased risk of meningioma 7 to 20 times higher when a patient is on CPA. The primary objective of this study was to determine the prevalence of CPA exposure in patients who had one or more intracranial meningiomas treated surgically or with radiation therapy. The secondary objectives were to establish a description of the patients who had intracranial meningioma in Nantes and to establish whether there was a difference in the intrinsic and tumoral characteristics of patients exposed to CPA compared with patients who had no hormonal exposure and patients who had been exposed to other hormones. METHODS: Monocentric, retrospective study including all patients treated by surgery or radiotherapy for intracranial meningioma from 2014 to 2017 excluding those with a history of exposure to ionizing radiation or neurofibromatosis type 2. RESULTS: 388 patients were included, 277 were treated by surgery and 111 by radiotherapy. 3.9% of the patients had a history or current use of CPA, 16.2% were taking other hormonal treatment. Compared with the group without hormonal exposure, the CPA-exposed group had significantly an earlier onset of meningiomas at 48.9 vs. 61.9 years (p = 0.0005) and had more multiple meningiomas, 26.7% vs. 6.1% (p = 0.0115). CONCLUSIONS: In our study, patients with a history or current use of CPA had significantly more meningiomas and were significantly younger at the onset.
Authors: S Zouaoui; A Darlix; V Rigau; H Mathieu-Daudé; F Bauchet; F Bessaoud; P Fabbro-Peray; B Trétarre; D Figarella-Branger; L Taillandier; H Loiseau; L Bauchet Journal: Neurochirurgie Date: 2018-03 Impact factor: 1.553
Authors: Rishi S Kotecha; Elaine M Pascoe; Elisabeth J Rushing; Lucy B Rorke-Adams; Ted Zwerdling; Xing Gao; Xin Li; Stephanie Greene; Abbas Amirjamshidi; Seung-Ki Kim; Marco A Lima; Po-Cheng Hung; Fayçal Lakhdar; Nirav Mehta; Yuguang Liu; B Indira Devi; B Jayanand Sudhir; Morten Lund-Johansen; Flemming Gjerris; Catherine H Cole; Nicholas G Gottardo Journal: Lancet Oncol Date: 2011-11-15 Impact factor: 41.316
Authors: Brian Custer; W T Longstreth; Leslie E Phillips; Thomas D Koepsell; Gerald Van Belle Journal: BMC Cancer Date: 2006-06-07 Impact factor: 4.430